Milad Karimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Milad Karimi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- John Brazier
Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK
7 shared publications - Aki Tsuchiya
University of Sheffield, Sheffield, UK
2 shared publications Maureen Rutten-Van Mölken
Erasmus school of health policy and management, Erasmus university
2 shared publicationsA. Chioti
Population Health Department, Luxembourg Institute of Health, Strassen, Luxembourg
1 shared publication- Andrea Kuemmerle
MMV Medicines for Malaria Venture Geneva Switzerland
1 shared publication Andrew Lloyd
Acaster Lloyd Consulting Ltd, London, UK
1 shared publication
Latest Publications
- 20 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (6_suppl) , 80
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US survey.
80 Background: Nine new treatments for mCRPC, each varying in efficacy and safety, have been approved over the last 10 years, changing the landscape of patient management. Understanding how patients perceive and value the efficacy, safety, and administration burden of these treatments can facilitate shared-decision making to determine optimal management. To our knowledge, this study is the first to elicit patient preferences for mCRPC treatments in the US. Methods: We conducted a cross-sectional survey using the discrete-choice experiment (DCE) method, in which participants were asked to state their choices over successive sets of treatment alternatives, defined by varying levels of treatment characteristics (i.e., attributes). Six treatment attributes in this DCE were examined: overall survival (OS), months until patients develop a fracture or bone metastasis, likelihood of requiring radiation to control bone pain, fatigue, nausea, and mode of administration. The levels taken by each of these attributes were selected to reflect clinical practice. Quota sampling was used in an online panel for recruitment to ensure that study sample is representative of the US prostate cancer population by age distribution. The choice responses were used to determine the value (i.e., preference weights) respondents placed on each attribute via the use of conditional and mixed logit models. The importance of attributes and marginal rates of substitutions were also calculated in order to understand how much patients were willing to trade off between different attributes. Results: The final dataset included 160 participants, with a mean age of 71.6 years old and a mean of 8.96 years since prostate cancer diagnosis. Participants noted their preferences for mCRPC treatments characteristics as follows (in decreasing order of importance over the attribute ranges included in the study): OS (relative attribute importance [RAI]: 31%), reduction in the need for bone pain control (23%), nausea (16%), months until patients develop a fracture or bone metastasis (15%), fatigue (11%), and mode of administration (3%). The marginal rates of substitution demonstrated that eliminating moderate nausea was perceived as equivalent to a 1.9-month reduction in OS, and a reduction of fatigue from severe to mild was perceived as equivalent to a reduction in OS of approximately 3.3 months. Conclusions: Improving OS remains the highest priority, but patients are willing to sacrifice some survival to avoid declines in quality of life, including avoiding bone pain/fracture, nausea, and fatigue, in the mCRPC disease state.
- 20 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (6_suppl) , 80
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US survey.
80 Background: Nine new treatments for mCRPC, each varying in efficacy and safety, have been approved over the last 10 years, changing the landscape of patient management. Understanding how patients perceive and value the efficacy, safety, and administration burden of these treatments can facilitate shared-decision making to determine optimal management. To our knowledge, this study is the first to elicit patient preferences for mCRPC treatments in the US. Methods: We conducted a cross-sectional survey using the discrete-choice experiment (DCE) method, in which participants were asked to state their choices over successive sets of treatment alternatives, defined by varying levels of treatment characteristics (i.e., attributes). Six treatment attributes in this DCE were examined: overall survival (OS), months until patients develop a fracture or bone metastasis, likelihood of requiring radiation to control bone pain, fatigue, nausea, and mode of administration. The levels taken by each of these attributes were selected to reflect clinical practice. Quota sampling was used in an online panel for recruitment to ensure that study sample is representative of the US prostate cancer population by age distribution. The choice responses were used to determine the value (i.e., preference weights) respondents placed on each attribute via the use of conditional and mixed logit models. The importance of attributes and marginal rates of substitutions were also calculated in order to understand how much patients were willing to trade off between different attributes. Results: The final dataset included 160 participants, with a mean age of 71.6 years old and a mean of 8.96 years since prostate cancer diagnosis. Participants noted their preferences for mCRPC treatments characteristics as follows (in decreasing order of importance over the attribute ranges included in the study): OS (relative attribute importance [RAI]: 31%), reduction in the need for bone pain control (23%), nausea (16%), months until patients develop a fracture or bone metastasis (15%), fatigue (11%), and mode of administration (3%). The marginal rates of substitution demonstrated that eliminating moderate nausea was perceived as equivalent to a 1.9-month reduction in OS, and a reduction of fatigue from severe to mild was perceived as equivalent to a reduction in OS of approximately 3.3 months. Conclusions: Improving OS remains the highest priority, but patients are willing to sacrifice some survival to avoid declines in quality of life, including avoiding bone pain/fracture, nausea, and fatigue, in the mCRPC disease state.
- 1 November 2019
- Published by Elsevier in Value in Health
- Vol. 22 (11) , 1311-1317
Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study
- 1 November 2019
- Published by Elsevier in Value in Health
- Vol. 22 (11) , 1311-1317
Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study
- 1 April 2019
- Published by Elsevier in Diabetes & Metabolism
- Vol. 45 (2) , 140-151
Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013–2015 European Health Examination Survey in Luxembourg
- 1 April 2019
- Published by Elsevier in Diabetes & Metabolism
- Vol. 45 (2) , 140-151
Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013–2015 European Health Examination Survey in Luxembourg
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1920
Aquablation of the prostate. Real-life data from 180 consecutive patients
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1920
Aquablation of the prostate. Real-life data from 180 consecutive patients
- Open Access
- 1 January 2019
- Published by Elsevier in Value in Health
- Vol. 22 (1) , 62-68
Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?
- 1 January 2019
- Published by Elsevier in Value in Health
- Vol. 22 (1) , 62-68
Open AccessFuture Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?
- Open Access
- 22 October 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Evaluating an integrated health and social care programme for vulnerable people: The case of ‘Better Together in Amsterdam North’
Van der Zwaan; Evaluating an integrated health and social care programme for vulnerable people: The case of 'Better Together in Amsterdam North' self-reported general health decreased but it increased for BSiN respondents. The same was the case for energy, independent problem solving, employment, volunteer-work, contact with neighbors, and loneliness. Discussion: BSiN appears to have a positive effect but the small sample size makes statistical evaluation challenging. In the first instance, future analysis will focus on including a larger sample and on using propensity score matching to improve the comparability of the intervention and control groups.
- 22 October 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Open AccessEvaluating an integrated health and social care programme for vulnerable people: The case of ‘Better Together in Amsterdam North’
Van der Zwaan; Evaluating an integrated health and social care programme for vulnerable people: The case of 'Better Together in Amsterdam North' self-reported general health decreased but it increased for BSiN respondents. The same was the case for energy, independent problem solving, employment, volunteer-work, contact with neighbors, and loneliness. Discussion: BSiN appears to have a positive effect but the small sample size makes statistical evaluation challenging. In the first instance, future analysis will focus on including a larger sample and on using propensity score matching to improve the comparability of the intervention and control groups.
- Open Access
- 22 October 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Investigating the association of integrated care on healthcare costs: evidence from a large retrospective cohort study in the Netherlands
Karimi; Investigating the association of integrated care on healthcare costs: evidence from a large retrospective cohort study in the Netherlands Preliminary regression analysis showed that people in integrated care had increased costs of around €180 and that this amount did not reduce over time. Discussion: Preliminary results indicate that integrated care programmes were associated with higher costs. Further analysis based on type of costs needs to indicate whether cost differences were likely to be due to severity of disease for integrated care patients or due to integrated care itself. Sensitivity analysis will be performed to assess robustness of the results. Future analysis will focus on the effect of different types of financing for these programmes and whether integrated care has a different effect on people with multimorbidity.
- 22 October 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Open AccessInvestigating the association of integrated care on healthcare costs: evidence from a large retrospective cohort study in the Netherlands
Karimi; Investigating the association of integrated care on healthcare costs: evidence from a large retrospective cohort study in the Netherlands Preliminary regression analysis showed that people in integrated care had increased costs of around €180 and that this amount did not reduce over time. Discussion: Preliminary results indicate that integrated care programmes were associated with higher costs. Further analysis based on type of costs needs to indicate whether cost differences were likely to be due to severity of disease for integrated care patients or due to integrated care itself. Sensitivity analysis will be performed to assess robustness of the results. Future analysis will focus on the effect of different types of financing for these programmes and whether integrated care has a different effect on people with multimorbidity.
- Open Access
- 24 July 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 576
Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA)
Evaluation of integrated care programmes for individuals with multi-morbidity requires a broader evaluation framework and a broader definition of added value than is common in cost-utility analysis. This is possible through the use of Multi-Criteria Decision Analysis (MCDA). This paper presents the seven steps of an MCDA to evaluate 17 different integrated care programmes for individuals with multi-morbidity in 8 European countries participating in the 4-year, EU-funded SELFIE project. In step one, qualitative research was undertaken to better understand the decision-context of these programmes. The programmes faced decisions related to their sustainability in terms of reimbursement, continuation, extension, and/or wider implementation. In step two, a uniform set of decision criteria was defined in terms of outcomes measured across the 17 programmes: physical functioning, psychological well-being, social relationships and participation, enjoyment of life, resilience, person-centeredness, continuity of care, and total health and social care costs. These were supplemented by programme-type specific outcomes. Step three presents the quasi-experimental studies designed to measure the performance of the programmes on the decision criteria. Step four gives details of the methods (Discrete Choice Experiment, Swing Weighting) to determine the relative importance of the decision criteria among five stakeholder groups per country. An example in step five illustrates the value-based method of MCDA by which the performance of the programmes on each decision criterion is combined with the weight of the respective criterion to derive an overall value score. Step six describes how we deal with uncertainty and introduces the Conditional Multi-Attribute Acceptability Curve. Step seven addresses the interpretation of results in stakeholder workshops. By discussing our solutions to the challenges involved in creating a uniform MCDA approach for the evaluation of different programmes, this paper provides guidance to future evaluations and stimulates debate on how to evaluate integrated care for multi-morbidity.
- 24 July 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 576
Open AccessStrengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA)
Evaluation of integrated care programmes for individuals with multi-morbidity requires a broader evaluation framework and a broader definition of added value than is common in cost-utility analysis. This is possible through the use of Multi-Criteria Decision Analysis (MCDA). This paper presents the seven steps of an MCDA to evaluate 17 different integrated care programmes for individuals with multi-morbidity in 8 European countries participating in the 4-year, EU-funded SELFIE project. In step one, qualitative research was undertaken to better understand the decision-context of these programmes. The programmes faced decisions related to their sustainability in terms of reimbursement, continuation, extension, and/or wider implementation. In step two, a uniform set of decision criteria was defined in terms of outcomes measured across the 17 programmes: physical functioning, psychological well-being, social relationships and participation, enjoyment of life, resilience, person-centeredness, continuity of care, and total health and social care costs. These were supplemented by programme-type specific outcomes. Step three presents the quasi-experimental studies designed to measure the performance of the programmes on the decision criteria. Step four gives details of the methods (Discrete Choice Experiment, Swing Weighting) to determine the relative importance of the decision criteria among five stakeholder groups per country. An example in step five illustrates the value-based method of MCDA by which the performance of the programmes on each decision criterion is combined with the weight of the respective criterion to derive an overall value score. Step six describes how we deal with uncertainty and introduces the Conditional Multi-Attribute Acceptability Curve. Step seven addresses the interpretation of results in stakeholder workshops. By discussing our solutions to the challenges involved in creating a uniform MCDA approach for the evaluation of different programmes, this paper provides guidance to future evaluations and stimulates debate on how to evaluate integrated care for multi-morbidity.
- Open Access
- 17 May 2018
- Published by Wiley in Health Economics
- Vol. 27 (8) , 1247-1263
An exploration of the non‐iterative time trade‐off method to value health states
Time Trade‐Off (TTO) usually relies on “iteration,” which is susceptible to bias. Discrete Choice Experiment with duration (or DCETTO) is free of such bias, but respondents find this cognitively more challenging. This paper explores non‐iterative TTO with or without lead time: NI(LT)TTO. In NI(LT)TTO, respondents see a series of independent pairwise choices without iteration (similar to DCETTO), but one of the two scenarios always involves full health for a shorter duration (similar to TTO). We compare three different “types” of NI(LT)TTO relative to DCETTO. Each type is presented in two “modes”: (a) verbally tabulated (as in a DCE) and (b) with visual aids (as in a TTO). The study has 8 survey variants, each with 12 experimental choice tasks and a 13th task with a logically determined answer. Data on the 12 experimental choices from an online survey of 6,618 respondents are modelled, by variant, using conditional logistic regressions. The results indicate that NI(LT)TTO is feasible, but some relatively mild states appear to have implausibly low predicted values, and the range of predicted values is much narrower than in DCETTO. The presentation of NI(LT)TTO tasks needs further improvement.
- 17 May 2018
- Published by Wiley in Health Economics
- Vol. 27 (8) , 1247-1263
Open AccessAn exploration of the non‐iterative time trade‐off method to value health states
Time Trade‐Off (TTO) usually relies on “iteration,” which is susceptible to bias. Discrete Choice Experiment with duration (or DCETTO) is free of such bias, but respondents find this cognitively more challenging. This paper explores non‐iterative TTO with or without lead time: NI(LT)TTO. In NI(LT)TTO, respondents see a series of independent pairwise choices without iteration (similar to DCETTO), but one of the two scenarios always involves full health for a shorter duration (similar to TTO). We compare three different “types” of NI(LT)TTO relative to DCETTO. Each type is presented in two “modes”: (a) verbally tabulated (as in a DCE) and (b) with visual aids (as in a TTO). The study has 8 survey variants, each with 12 experimental choice tasks and a 13th task with a logically determined answer. Data on the 12 experimental choices from an online survey of 6,618 respondents are modelled, by variant, using conditional logistic regressions. The results indicate that NI(LT)TTO is feasible, but some relatively mild states appear to have implausibly low predicted values, and the range of predicted values is much narrower than in DCETTO. The presentation of NI(LT)TTO tasks needs further improvement.